A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers

A Placebo-Controlled, Phase I, Single-center Evaluation of the Single-dose Pharmacokinetics Study of Azilsartan Trimethylethanolamine

The purpose of this study is to evaluate the Pharmacokinetics and safety of Azilsartan Trimethylethanolamine in healthy volunteers

Inclusion Criteria:

• Healthy males or females
• Aged from 18 years to 45 years
• Body mass index (BMI) 19 to 25kg/m2

Exclusion Criteria:

• Has a known sensitivity to angiotensin II receptor blocker（ARB）
• With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor
• Has known or suspected history of alcoholism or drug abuse or misuse
• With a history of laboratory results that show the presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV)
• Pregnant,lactating，menstrual
• Vegetarian
• Postural hypotension
• Systolic blood pressure<100mmHg，or>130mmHg;and/or diastolic blood pressure<70mmHg,or>90mmHg